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Respiratory gatingBackground and purpose: Respiratory motion during proton therapy can severely degrade dose distribu-
tions, particularly due to interplay effects when using pencil beam scanning. Combined rescanning and
gating treatments for moving tumors mitigates dose degradation, but at the cost of increased treatment
delivery time. The objective of this study was to identify the time efficiency of these dose degradation-
motion mitigation strategies for different range of motions.
Materials and methods: Seventeen patients with thoracic or abdominal tumors were studied. Tumor
motion amplitudes ranged from 2–30 mm. Deliveries using different combinations of rescanning and gat-
ing were simulated with a dense dose spot grid (4  4  2.5 mm3) for all patients and a sparse dose spot
grid (8  8  5 mm3) for six patients with larger tumor movements (>8 mm). The resulting plans were
evaluated in terms of CTV coverage and time efficiency.
Results: Based on the studied patient cohort, it has been shown that for amplitudes up to 5 mm, no
motion mitigation is required with a dense spot grid. For amplitudes between 5 and 10 mm, volumetric
rescanning should be applied while maintaining a 100% duty cycle when using a dense spot grid.
Although gating could be envisaged to reduce the target volume for intermediate motion, it has been
shown that the dose to normal tissues would only be reduced marginally. Moreover, the treatment time
would increase. Finally, for larger motion amplitudes, both volumetric rescanning and respiratory gating
should be applied with both spot grids. In addition, it has been shown that a dense spot grid delivers bet-
ter CTV dose coverage than a sparse dose grid.
Conclusion: Volumetric rescanning and/or respiratory gating can be used in order to effectively and effi-
ciently mitigate dose degradation due to tumor movement.
 2021 Published by Elsevier B.V. Radiotherapy and Oncology 160 (2021) 82–89Proton therapy has become a technique that has spread world-
wide with the construction of many proton therapy centers, most
of which deliver pencil beam scanning (PBS). However, the major
issue with PBS proton therapy is the handling of intrafractional
motion. The strong range dependence and interplay effect of PBS
lead to significant degradation of the dose distribution in the pres-
ence of intrafractional motion. This results in inhomogeneous dose
distributions with local under- and over-dosage in the target and
over-dosage in the surrounding normal tissues [1–3]. Various
motion mitigation techniques have been developed to mitigate
motion effects for PBS based treatments and which maintain target
conformity of the delivered dose distributions [4–7,2].
Breath-hold [8] and beam gating [9–11] techniques can both
reduce the interplay effect by controlling the motion amplitude.However, firstly, not every patient is able to hold his/her breath
during treatment. Secondly, although it has been shown that gat-
ing becomes important when tumor motion is large [12], gating
increases considerably the treatment time and residual interplay
effects may still need to be addressed. Another technique, so-
called beam tracking, would have the potential to adapt the
scanned beam to target motion laterally as well as longitudinally
in depth [13–15], but has not yet been used clinically. Alterna-
tively, rescanning [1] has the potential to average out the local
over- and under-dosage by delivering the fraction dose in repeated
scans. Several approaches to rescanning have been proposed. Pre-
vious studies have shown its impact on the final dose distribution,
such as the quantification of the interplay effects as well as plan
robustness, but it’s effectiveness can be machine specific [16]. On
the other hand, although this technique has proven its effective-
ness for mobile tumors in many previous studies [17–21], the tar-
get volume has to be extended to cover the whole motion of the
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becomes larger as motion amplitudes increase [22,20].
Previously at PSI, all patients were treated only with volumetric
rescanning, restricting the treatments to moderately moving tar-
gets (motions< 8 mm). The introduction of an optical tracking sys-
tem into our clinic opened the possibility of gated delivery [23],
with the effectiveness of combined gating and rescanning for treat-
ing mobile targets with proton PBS being demonstrated in previous
studies [10]. However, both techniques increase considerably the
time needed for the delivery, particularly with gating. Thus, this
study aims to identify which combinations of gating and rescan-
ning lead to clinically acceptable results and, among those, to iden-
tify the most time-efficient combinations.
This study is a systematic analysis of the effectiveness and
efficiency of clinically applied motion mitigation strategies and




In order to simulate 4D treatments, available patient data sets
with moving tumors were investigated. A total of 17 patients
were studied, including different anatomical tumor sites such
as thorax and abdomen (Table 1). Patients 1–5, 8, 14–17, have
been previously treated at PSI, whereas patients 6–7, 9–13,
have not been treated at PSI, but were considered as test cases.
The clinical target volume (CTV) of each patient can be found
in Table 1. Moreover, in this study, the original treatment pre-
scription was kept, but only one fraction was analysed. The
dose was chosen based on the original treatment prescription
for PSI patients. They varied between 0.3 and 5 Gy/fraction,
see Table 1. For non-PSI patients, we chose a dose of 2 Gy/frac-
tion (not the prescription), because this data was not provided.
II. Motion extraction
Every patient had a 4DCT in order to take into consideration
the tumor motion, and provides time-resolved density infor-
mation for both treatment planning and delivery [24–28]. To
quantify the motion during a breathing cycle, deformable
image registration (DIR) has been used [29–34] and perfectly
regular breathing assumed for each patient. In this way, CTV
motion through a respiratory cycle could be extracted for
every patient.
The CTV motion in this study was defined as the median of
the peak-to-peak displacement of the centre of each voxelTable 1








Unconst. SI motion ampl.
(mm)
1 Lung 129 1.87
2 Thoracic wall 774 2
3 Lung 163 2.45
4 Thoracic wall 167 2.45
5 Lung 1228 4.53
6 Thoracic wall 74 5.57
7 Thoracic wall 59 5.69
8 Liver 42 6.59
9 Thoracic wall 24 6.64
10 Thoracic wall 56 7.73
11 Thoracic wall 67 8.44
12 Thoracic wall 107 11.36
13 Thoracic wall 6 12.14
14 Abdomen 218 12.95
15 Liver 47 14.76
16 Liver 75 21.79
17 Liver 21 30.07
83contained in the CTV throughout all phases. From this,
the motion range of the CTV over the entire breathing cycle
in the superior-inferior (SI) direction, anterior-posterior (AP)
direction, and left–right (LR) direction have been extracted.
The CTV movement in the SI direction within the entire
breathing cycle was the largest motion for every patient,
with unmitigated CTV motion in the SI direction for all
patients covering a range from 1.87 mm to 30.07 mm
(Table 1). Breathing periods extracted from the 4DCT tem-
poral resolution can be found in Table 1 for all patients.
III. Motion mitigation techniques
Both respiratory gating and hybrid volumetric scaled rescan-
ning techniques have been considered in this study as motion
mitigation strategies.
A. Respiratory gating
A gating window was defined as the number of breathing
phases in the 4DCT. As such, the gating window definition
is not amplitude-based. Since exhalation is the most
reproducible respiratory state, the exhale phase has been
selected to treat tumors [35,36] and a gating window
defined as the number of phases around the full exhala-
tion phase. Hence, each gating window determined a duty




















DC ¼ Number of phases within the gating window
Total number of phases within a respiratory cycle
:
For our study, different DCs were investigated to attenu-
ate residual tumor movement, that is, the movement of
the target volume within the gating window. The follow-
ing four DCs were chosen for every patient: a 100% DC,
which included all breathing phases (i.e. no gating) a
60% DC, a 50% DC and a 40% DC.B. Volumetric rescanning
In clinical practice, our institution uses volumetric, hybrid
scaled rescanning, enabled by fast energy changes of the
gantry beamline [37,1,3,38,17,39]. For this, the dose of
every spot is divided by the number of rescans (NR),
referred to as scaled repainting. However, when spots
are too low-weighted, these cannot be sub-divided. As a
consequence, if a spot cannot be divided by the nominal
number of rescans (NR), the number of spot-specific res-
cans will be reduced as necessary. Thus, some spots with
very low weights will be delivered only once. Hybrid
scaled volumetric rescanning with NRs from 1–9 have
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Time efficient proton 4D treatmentsIV. Machine characteristics
In this paragraph, some important features of the proton
machine are presented. Detailed machine characteristics can
be found in [3,37,40–42]. To allow a fast two-dimensional
scanning, two sweeper magnets (U and T direction) are
installed on the gantry. The scanning speeds are of 0.5 cm/
ms in U-direction (dispersive direction) and of 2 cm/ms in T-
direction (transverse to the magnets). The energy variation is
performed right after the cyclotron using a degrader (S axis).
A typical beam energy change of 3 MeV for typical range steps
of 5 mm water equivalent can be made within 80 ms.
The energy can be changed in the range between 70 MeV and
230 MeV. The components in the nozzle are designed to have
as little material as possible in the beam path. This maintains a
small spot size, r ¼ 3 4mm, at all energies.
V. Treatment planning
A geometrical internal target volume (gITV) [22] was gener-
ated for every patient in order to consider anatomical changes
due to breathing during both treatment planning and treat-
ment delivery [43–45]. The gITV is defined as the volume
including all clinical target volume (CTV) positions at all respi-
ratory phases during the respiratory cycle when the beam is
on. Finally, to account for uncertainties during treatment
delivery such as patient positioning errors, a margin of
7 mm has been added to the gITV for the treatment planning
process, defining the planning target volume (PTV).
For treatment planning, a synthetic static CT has been created
from a 4DCT for the optimization process, in order to limit
plan degradation due to respiratory motion [46,45].
In a first step, the maximum intensity of all breathing phases
per voxel in the gITV was calculated, referred to as an intensity
filling overwrite [46]. This step was necessary to position the
Bragg peaks in low-density tissues during the treatment plan-
ning procedure. Then, in a second step, and in order not to plan
the treatment on a specific respiratory start phase, voxel-wise
Hounsfield units outside the gITV were averaged over all
breathing phases. As a result, a synthetic static CT has been
created from a 4DCT for the optimization process, limiting
plan degradation due to respiratory motion [46,45].
Based on this synthetic static CT, multiple field clinical treat-
ment plans were created for each patient. The treatment fields
were selected so that they best cover the tumor while avoiding
neighbouring critical structures and organs [47]. Each field
was individually optimized through a single field uniform
dose (SFUD) optimization, so that each field delivered homo-
geneous target dose coverage [47].
VI. 4D dose calculation
Treatment deliveries were simulated using the PSI in–house
4D dose calculation (4DDC) engine described by Boye et al.
[48] and Krieger et al. [49]. The 4DDC is able to show the
motion effects on the static dose distributions. The PSI in–
house made 4DDC algorithm is based on both the ray casting
algorithm and on a deformable dose grid algorithm. The idea
of this PSI 4DDC is to calculate the dose of each pencil beam
based on an individual time stamp while taking into account
deformations and displacements over the breathing cycle of
the 4DCT. The 4DDC uses the motion vector field extracted
from the 4DCT to deform the dose calculation grid as function
of time. Based on 4DCT information, water-equivalent path
lengths and density information are adapted for every point
in time.
All plans have been calculated with a spot grid size of
4  4  2.5 mm3 (2.5 mm is the energy layer spacing in water)
as used clinically in our institution [41]. In addition, patients
11–16 (with larger tumor motions) have also been calculated
with a sparser spot grid, 8  8  5 mm3, which may be more84representative for other institutions (Table 1). The 4  4  2.
5 mm3 spot grid and the 8  8  5 mm3 spot grid have spots
spacing of 4  4 mm2 and 8  8 mm2, respectively, and energy
layers spacing of 2.5 mm and 5 mm water equivalent, respec-
tively.
For each defined field in a patient’s treatment plan, a delivery
start phase needs to be chosen. However, since the start of the
delivery is not synchronizedwith the respiration of the patient,
all possible combinations of starting phases, within the respec-




factor, is given by:ðnumber of breathing phases in the gating windowÞnumber of fields
ð1Þ
As a result, with an average of 2.4 fields for each treatment
plan, more than 7000 dose distributions have been calculated
in total (Eq. (1), Table 2). In combination with the different
phases per 4D scenario, this has resulted in more than
300’000 dose distributions having been calculated in total.VII. Evaluation
CTV dose coverage has been assessed by the percentage of vol-
ume receiving at least 95% of dose (V95%). Once all dose distri-
butions have been calculated, CTV dose coverage was analysed
for every combination of NR and DC for all patients. For each
patient, many different dose distributions have been obtained
for one DC combined with one possible NR, due to combina-
tions of all respiratory start phases for all fields (Table 2).
Therewith, the distribution of all V95% values can be visual-
ized as a single box in a boxplot. For every patient, up to 9 res-
cans were applied for each DC. Hence, for each DC, there were
9 different combinations with volumetric rescanning. For each
combination there are different respiratory start phases for all
fields. In that respect, each combination can be visualised as a
single box in a boxplot. Thus, 9 boxes per DC were represented
in each boxplot - a total of 36 ((9 boxes per DC) * (4 DC)) boxes
for each patient.
To assess the quality of the patient’s treatment plan (TP) under
conditions of motion, only plans meeting the following condi-
tion were considered: The 25th percentile of the V95% must be
P95% for a particular combination of rescanning and gating.
The 25th percentile (1st quartile) was chosen instead of the
minimum value, as only one bad combination could already
exclude the plan, while the others could be very good combi-
nations. In addition, it is clinically reasonable to be above 95%.
However, not all acceptable patient treatment plans are also
time efficient. Due to the repetitive beam interruptions when
gating is applied, the treatment time increases considerably.
Consequently, we can define this increase of time compared
to a non-mitigated delivery as the gating time penalty, tG. In
our case, tG, is not patient-specific, but simply given by a factor
of 100/DC, where DC is the duty cycle considered (Fig. 1). In
contrast, as illustrated in Fig. 1, the hybrid scaled volumetric
rescanning time penalty, tR, is patient-specific. Thus, for a par-
ticular combination of DC and number of rescanning (NR) for a
specific patient, the total time penalty TTP for delivering such a
combination is simply given by:TTP ¼ tG  tR
Therefore, from all acceptable patient treatment plans, only
those that were most time efficient were considered clinically
feasible treatment plans.
Table 2
Total number of calculated dose distributions using different spot grid sizes and different combinations of duty cycles (DC) and number of rescanning (NR). Abbreviations: DC:
duty cycle; NR: number of rescanning.
Spot grid DC = 100% DC = 60% DC = 50% DC = 40% Total with 1 NR Total with up to 9 NR
4  4  2.5 mm3 3’277 992 612 335 5’215 234’675
8  8  5 mm3 1’243 364 226 125 1’958 88’130
7’173 322’805
Fig. 1. Left: Gating time penalty, tG . Right: Hybrid volumetric rescanning time penalty, tR for every patient.
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In the following, the results using a dense spot grid of 4  4 
2.5 mm3 and a sparse spot grid of 8  8  5 mm3 will be illustrated
for a patient (Patient ID: 16) with a large CTV SI motion (22 mm)
without gating (DC = 100%). Fig. 2 shows this patient’s boxplot
when using the dense spot grid. Each box is positioned on the x-
axis according to the time needed to deliver it, with each DC having
a specific color: green for DC = 100%, yellow for DC = 60%, blue for
DC = 50% and pink for DC = 40%. Each combination of DC and NR is
represented as a single box in a boxplot. As time increases, boxes of
the same color represent an increasing NR from left to right. Fur-
thermore, for each DC, the V95% value was extracted for the static
case. Since the V95% values for each DC in the static case were all
similar, the mean value was calculated and plotted as a solid black
line in the boxplot. As illustrated in Fig. 2, it can be noticed that
CTV dose coverage may decrease with increasing number of volu-
metric rescans due to interplay effects. If the number of rescans is
increased, the time per rescan decreases because there is less dose
delivered with each rescan. This means that the regularity between
the rescan and breathing changes with the number of rescans. If
every rescan starts in the same respiratory phase, the advantage
of rescanning is lost and such interplay effects can occur. The same
effects were observed in [10].
From all the boxplots of each patient, the CTV dose coverage
was analysed with the following criterion: if the first quartile of
a box was greater than or equal to 95% for V95%, then the plan,
consisting of a specific combination of DC and NR, was considered
an acceptable treatment plan. The combinations meeting this crite-
rion for patient number 16 are illustrated in the left panel of Fig. 3a
for a spot grid size of 4  4  2.5 mm3. The right panel of Fig. 3a
illustrates the same information for the larger spot spacing
(8  8  5 mm3). It is seen that the overall delivery time is
decreased by using a larger spot spacing. Nevertheless, less combi-
nations of rescanning and gating are clinically acceptable (V95%
P95%). All the results are summarized in Fig. 3b.85For every patient however, not all plans which meet the V95%
P95% condition are efficient in terms of time (Fig. 3a left). In order
to maintain a certain clinical workflow, and to avoid organ drift
and patient movements over the fraction, only the most time effi-
cient plans with V95% P95% were considered as clinically possible
treatment plans. The most clinically feasible plan for each patient
was then defined as the plan with the lowest delivery time that
provided a target coverage of V95% P95%. These are presented in
Table 3 with a spot grid size of 4  4  2.5 mm3 for all patients
(1–17) and with a spot grid size of 8  8  5 mm3 for patients
11–16.
In addition, the mean and maximum dose to the organ at risks
(OARs) have been investigated for the two different spot grids.
Regarding the mean dose reduction compared to the 100% DC with
the clinical (dense) spot grid, a reduction of up to 3% could be
achieved with a 40% DC for tumor motions below 5 mm, a reduc-
tion up to 4% with a 40% DC for intermediate tumor motions (5–
10 mm), and a reduction up to 12% with a 40% DC for large tumor
motions. With the sparser dose grid, dose to OARs can be reduced
up to 5% for a 100% DC for large tumor motions. Regarding the
maximum dose reduction compared to the 100% DC with the clin-
ical spot grid, a reduction up to 4% to OARs could be achieved with
a 40% DC for tumor motions below 5 mm, a reduction up to 12%
with a 40% DC for intermediate tumor motions (5–10 mm), and a
reduction up to 15% with a 40% DC for large tumor motions. For
more details, please refer to the supplementary materials.Discussion
In this study, we systematically investigated both the effective-
ness of combined gating and rescanning for treating moving tar-
gets with PBS (efficacy) and the efficiency in terms of treatment
delivery time. We did this comprehensive investigation with 17
very different real patients, we used the original clinical prescrip-
tions, we looked at different tumor sites (such as lung, liver, pan-
creas), and we looked at a very wide unconstrained motion
Fig. 2. Top: V95% distributions for all combinations of duty cycles (DC) and number of rescanning (NR) for patient number 16, using a spot grid size of 4  4  2.5 mm3. Each
box is positioned on the x-axis according to the time needed to deliver it. For each color, the first box from the left shows the combination of the respective DC with 1 NR. The
second box from the left for the same color shows the combination of the respective DC with 2 NR. Bottom: zoom in the region near the static case of the top boxplot.
Abbreviation: DC: duty cycle.
Time efficient proton 4D treatmentsamplitude interval. This study is a systematic analysis of the effec-
tiveness and efficiency of clinically applied motion mitigation
strategies and may serve as a clinical guideline for future treat-
ments of mobile tumors.
The objective of this work was to identify the time efficiency of
combined rescanning and gating treatments of moving tumors
with proton pencil beam scanning in order to attenuate dose
degradation due to tumor movement. For this purpose, treatment
plans have been calculated with a clinical spot grid for seventeen
patients (1–17 in Table 1), and, in addition, with a sparser dose grid
for six patients (11–16 in Table 1) whose CTV SI motions were
almost always the largest motions in the full duty cycle (DC
= 100%). Each plan has been analysed in terms of CTV dose cover-
age and delivery time efficiency. The plans meeting the condition
V95% P95% where considered clinically acceptable, and among
those, the most time efficient where identified. The time efficiency
of a treatment plan is clinically important to avoid organ drift and
patient movements over a fraction, as well as for the patient com-
fort. Indeed, this was the main purpose of this study as the effec-
tiveness of combined rescanning and gating treatments for
moving tumors with proton spot scanning has been demonstrated
in previous studies [10].
In clinical practice, V95% P95% is a common requirement to
accept a treatment plan. Dose degradation within this criterion is
clinically acceptable in clinical practice. During this study, it was
seen that the better the V95%, the better the homogeneity of the
dose. However, unlike the V95%, there is no clear acceptance mea-
sure for the dose homogeneity within the target. Moreover, even
without motion (static case), the homogeneity in terms of D5%-86D95% was very different from one patient to another, making it dif-
ficult to define a threshold value. The D5%-D95% parameter heavily
depends on the patient geometry and the tissue homogeneity.
Therefore, V95% P95% was the only quantifiable criterion taken
into account in deciding whether the plan was clinically accept-
able. The visual comparison between the V95% and the D5%-
D95% (see supplementary material for patient number 16) revealed
the same patterns as a function of the number of rescans and the
gating window. D5%-D95% implicitly also contains both cold and
hot spots, which can occur under motion conditions. Furthermore,
both the results for the D2% as well as the D5%-D95% revealed the
same patterns as the V95%.
Based on the obtained gating and rescanning time penalties, it
has been shown that gating penalizes more time than rescanning
for small and intermediate motions and vice versa for large
motions. Therefore, based on the studied patient cohort, and using
the clinical spot grid size of 4  4  2.5 mm3, we would advise that
for tumor motions smaller than 5 mm no motion mitigation is
required in order to preserve both time efficiency and acceptable
treatment quality. For intermediate movements (5–10 mm), fewer
number of rescans should be applied while maintaining a 100% DC
with the clinical spot grid. Although a 100% DC should be main-
tained to achieve more time efficient plans, gating could be envis-
aged to reduce the target volume. Nonetheless, it has been shown
that respiratory gating does not necessarily reduce dose to normal
tissues, or only marginally, for intermediate motions. Finally, for
large to extremely large movements (10–30 mm), both gating
and rescanning should be applied with both spot grids. Conse-
quently, by applying gating, the dose to normal tissues could be
Fig. 3. a) Left: Combinations that meet V95% P95% using the clinical (dense) spot grid for patient number 16. Right: Combinations that meet V95% P95% using the sparser
spot grid for patient number 16. b) Combinations that meet V95%P95% using a spot grid size of 4  4 2.5 mm3 for patients 1–17 and using a spot grid size of 8 8  5 mm3
for patients 11–16.Abbreviations: DC: duty cycle; NR: number of rescanning.
P. Gut, M. Krieger, T. Lomax et al. Radiotherapy and Oncology 160 (2021) 82–89reduced up to 12% for the patient with the largest CTV SI motion
using a 40% DC and the clinical spot grid.
It has also been shown that the spot grid size influences the
results. Although the time needed to deliver the same plan is
slightly reduced using the sparser spot grid (less spots), the denser
spot grid gave better CTV dose coverage for all plans. By this
means, except for one patient, the most time efficient plan using
the 4  4  2.5 mm3 spot grid would even not be acceptable with
the 8  8  5 mm3 spot grid.87Even though our results are only valid for this patient cohort
and for a fast energy switching delivery machine, these results
can be taken as a starting point for PBS based treatment of future
patients with thoracic and abdominal tumors. The 4DDC will still
be required in all future cases. A more extensive investigation
could also be conducted when considering the extent of motion
of the CTV as a definition of the gating window. Another limitation
of this study is that we relied on a single 4DCT per patient, which
assumes that the patient breathes the same way during the treat-
Table 3
Patient are listed by increasing unconstrained CTV SI motion amplitude (column 2), that is, the CTV SI motion in the 100% duty cycle (DC). The 3rd column shows the most time
efficient plans having V95% P95% using a 4  4  2.5 mm3 spot grid. The column 4 shows the corresponding delivery time. The 5th column shows the most time efficient plans
having V95% P95% using a 8  8  5 mm3 spot grid. The column 6 shows the corresponding delivery time. Abbreviations: CTV: clinical target volume; SI: superior-inferior; No.
fields: number of fields; DC: duty cycle; NR: number of rescanning.
Patient ID CTV SI motion (mm) 4  4  2.5 mm3 Time (min) 8  8  5 mm3 Time (min) No. fields
1 1.87 DC = 100% NR = 1 1.6 2
2 2 DC = 100% NR = 2 9.7 2
3 2.45 DC = 100% NR = 1 1.4 1
4 2.45 DC = 100% NR = 1 4.8 3
5 4.53 DC = 100% NR = 1 7.0 2
6 5.57 DC = 100% NR = 2 2.0 3
7 5.69 DC = 100% NR = 3 1.7 2
8 6.59 DC = 100% NR = 1 2.3 3
9 6.64 DC = 100% NR = 2 1.6 3
10 7.73 DC = 100% NR = 3 1.7 3
11 8.44 DC = 100% NR = 2 2.1 DC = 100% NR = 4 2.3 3
DC = 40% NR = 1 3.1
DC = 50% NR = 2 3.2
DC = 60% NR = 3 3.2
12 11.36 DC = 100% NR = 3 3.3 DC = 40% NR = 1 3.7 3
DC = 50% NR = 1 3.9
DC = 60% NR = 2 4.2
13 12.14 DC = 60% NR = 3 1.8 DC = 60% NR = 4 1.8 2
DC = 50% NR = 5 2.4 DC = 40% NR = 2 1.9
DC = 50% NR = 3 1.9
14 12.95 DC = 50% NR = 1 3.9 DC = 60% NR = 3 3.4 2
DC = 60% NR = 2 4.7 DC = 50% NR = 2 3.5
DC = 40% NR = 1 4.9
15 14.76 DC = 100% NR = 3 3.5 DC = 100% NR = 3 2.8 2
DC = 60% NR = 1 3.6
16 21.79 DC = 60% NR = 3 5.9 3
DC = 50% NR = 2 5.9 DC = 40% NR = 4 7.8
DC = 40% NR = 1 6.1
17 30.07 DC = 50% NR = 2 3.2 2
DC = 100% NR = 8 3.7
DC = 40% NR = 1 3.7
Time efficient proton 4D treatmentsment delivery, and ignored any possible variation in motion,
whether intra- or inter-fractional. However, respiratory patterns
vary from one fraction to another and even within a fraction, espe-
cially in the case of free breathing. That is why coaching could be
applied to improve the reproducibility of respiration using external
surrogates to monitor breathing [50]. Last but not least, we did not
simulate any fractionation, this would, however, act as an addi-
tional ’rescanning’ [51], and thus over the whole treatment, more
rescanning/gating combinations might become clinically
acceptable.Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, athttps://doi.org/10.1016/j.radonc.2021.03.041.References
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